Why Anti-VEGF Injections Need Close Specialist Monitoring
Understanding Anti-VEGF Treatment
VEGF stands for vascular endothelial growth factor. It is a natural protein your body uses to create new blood vessels. This process is normally helpful for healing wounds and growing tissue. In certain eye diseases, however, the eye produces too much VEGF. This excess protein causes fragile, abnormal blood vessels to grow in or beneath the retina.
These abnormal vessels leak blood and fluid into the retina. The leakage causes swelling, damages light-sensing cells, and leads to vision loss. The medical term for this swelling is macular edema. Left untreated, the damage can become severe and permanent.
Anti-VEGF medications are injected directly into the eye in a procedure called an intravitreal injection. The medication blocks excess VEGF before it can trigger new blood vessel growth or leakage. By intercepting this protein, the drug allows the retina to begin healing. Fluid and swelling often decrease, and vision may stabilize or improve.
Anti-VEGF treatment improves vision in about one out of three patients. For roughly nine out of ten patients, it at least stabilizes vision and prevents further loss (AAO).
Retina specialists use anti-VEGF injections to treat several sight-threatening conditions. The most common include:
- Wet age-related macular degeneration (wet AMD), where abnormal blood vessels grow beneath the macula
- Diabetic macular edema (DME), swelling in the central retina caused by diabetes
- Diabetic retinopathy (DR), damage to retinal blood vessels from high blood sugar
- Retinal vein occlusion (RVO), a blockage in a vein that drains blood from the retina
Available Anti-VEGF Medications
Several anti-VEGF drugs have been used for years and have strong track records. Lucentis (ranibizumab) was the first anti-VEGF medication approved specifically for eye use. Eylea (aflibercept) became the most commonly used option, typically given every four to eight weeks after an initial loading phase. Avastin (bevacizumab) is FDA-approved for cancer but is widely used off-label for retinal conditions. Large clinical trials have shown Avastin to be effective for many retinal diseases, though it is not FDA-approved for eye use.
Newer medications may reduce how often patients need injections. Vabysmo (faricimab) is a bispecific antibody that targets both VEGF and a second protein called angiopoietin-2. This dual action may provide a longer-lasting effect. Some patients on Vabysmo can extend their visits to every four months after the initial loading doses.
Eylea HD (high-dose aflibercept) delivers a higher concentration of the same proven drug. After initial monthly doses, some patients may go eight to sixteen weeks between injections. These newer options help reduce the number of office visits while maintaining strong results.
For patients who face a heavy injection burden, researchers developed the ranibizumab port delivery system (Susvimo). This tiny implant, about the size of a grain of rice, is surgically placed in the eye. It continuously releases ranibizumab into the eye through passive diffusion. Patients with this implant may only need to visit their retina specialist twice a year to have the device refilled, rather than receiving monthly injections. The FDA approved Susvimo for diabetic macular edema in February 2025.
Who Receives Anti-VEGF Injections and Risk Factors
Anti-VEGF injections are used for patients whose retinal disease involves abnormal blood vessel growth or fluid leakage. Not every patient with a retinal condition needs these injections. A retina specialist determines whether treatment is appropriate based on the specific type and severity of disease.
No two cases of wet AMD, retinal vein occlusion, or diabetic retinopathy are the same. The decision about what to treat, when to treat, and whether to adjust or stop treatment can have major implications for a patient's long-term vision.
While anti-VEGF injections are generally safe, there are known risks. The most serious but rare complications include:
- Endophthalmitis (a severe eye infection), occurring in about 1 in 2,000 injections (All About Vision)
- Sterile intraocular inflammation, a non-infectious inflammatory reaction
- Retinal detachment (separation of the retina from the back of the eye)
- Bleeding inside the eye (vitreous hemorrhage)
- Cataract development or progression
- Sustained elevated intraocular pressure (IOP), which may require closer monitoring in patients who have glaucoma
Most anti-VEGF drugs share a similar safety profile. However, Beovu (brolucizumab) carries a specific risk of retinal vasculitis (inflammation of blood vessels in the retina). This condition, known as brolucizumab-associated retinal vasculitis, is a newly recognized adverse event unique to that drug. A retina specialist carefully weighs these risks when choosing the best medication for each patient.
Why Regular Monitoring Matters
A retina specialist uses advanced imaging at each visit to assess how the eye is responding to treatment. Optical coherence tomography, or OCT, is a non-invasive scan that creates detailed cross-section images of the retina. It reveals whether fluid or swelling is present, improving, or worsening. Fluorescein angiography (FA) uses a special dye and camera to photograph blood flow in the retina and detect leaking vessels.
These tests guide critical decisions. They help the specialist determine whether the current medication is working, whether the dose interval should be adjusted, or whether a different drug would be more effective.
Anti-VEGF treatment is not one-size-fits-all. Retina specialists use several approaches to tailor the injection schedule to each patient. One common method is called treat-and-extend. When imaging shows that leakage is under control, the specialist gradually spaces injections further apart. If fluid returns, the interval is shortened again.
Another approach is pro re nata (PRN), also called treat-and-observe. In this method, a patient receives three initial monthly injections, then returns for regular monitoring. Additional injections are given only when imaging shows new or worsening fluid. Both approaches aim to use the fewest possible injections while keeping the retina as dry and healthy as possible.
Research shows that skipping or delaying injections can lead to permanent vision loss. A study of wet AMD patients found that those who received 21 or fewer injections over five years experienced the greatest losses in visual acuity. Even patients who received up to 43 injections over five years still lost some vision on average (Retina Today, 2021). These findings highlight the importance of consistent follow-up and treatment adherence.
Chronic retinal conditions like wet AMD, diabetic macular edema, and retinal vein occlusion often require ongoing treatment over months or years. Missing appointments can allow fluid to return and damage the retina before you notice any change in your vision.
Retina specialists are ophthalmologists who have completed additional fellowship training in diseases and surgery of the retina and vitreous. They have the most experience interpreting OCT scans, reading angiograms, and recognizing subtle signs that treatment needs to change. Many retina specialists believe that patients face unnecessary risks when receiving anti-VEGF injections from a provider who does not specialize in retinal care.
Deciding when to treat, when to extend intervals, and when to switch medications requires deep familiarity with retinal disease behavior. A retina specialist is best equipped to make these nuanced clinical decisions.
What to Expect During Treatment
An intravitreal injection is performed in the office. The eye is numbed with anesthetic drops, and the surface is cleaned with an antiseptic solution to reduce infection risk. The specialist then uses a very fine needle to inject the medication through the white part of the eye (the sclera) into the vitreous cavity, which is the gel-filled space inside the eye. The procedure typically takes only a few minutes.
Most patients feel pressure or mild discomfort during the injection. Some soreness, redness, or a gritty sensation may last for a day or two afterward. Small red spots on the white of the eye are common and usually clear within a week or two.
During the loading phase, injections are typically given monthly for three consecutive months. After that, the schedule depends on the medication used and how the eye responds. With older anti-VEGF drugs, some patients need injections every four to six weeks. With newer options like Vabysmo (faricimab) or Eylea HD (high-dose aflibercept), some patients may extend intervals to every three or four months.
Even during extended intervals, regular monitoring visits are important. A retina specialist may schedule imaging appointments between injections to confirm the retina remains stable.
Retinal diseases are chronic, and treatment needs can change. A medication that works well at first may become less effective over time. The specialist may switch to a different anti-VEGF drug, adjust the interval, or add complementary treatments. This ongoing assessment is one of the most important reasons to maintain a relationship with a retina specialist throughout your care.
Warning Signs That Require Immediate Attention
Some mild discomfort after an injection is normal. However, certain symptoms after an injection may indicate a serious complication. Contact your retina specialist right away if you experience:
- Increasing eye pain that does not improve within a day
- Significant redness that worsens rather than improves
- A noticeable decrease in vision
- New floaters, flashes of light, or a shadow or curtain over part of your vision
- Significant swelling of the eye or eyelid
Some symptoms require urgent evaluation whether or not you have recently had an injection. See a retina specialist or go to the emergency room immediately if you experience a sudden increase in floaters, flashes of light, a curtain or shadow spreading across your vision, or sudden vision loss in one eye. These symptoms can indicate retinal detachment or other emergencies that need immediate treatment to protect your sight.
Living With Ongoing Anti-VEGF Treatment
Frequent office visits and injections can be challenging, especially for older adults or those with transportation difficulties. Planning ahead can help. Some patients schedule several months of appointments at once. Others arrange rides with family members or community services.
Communicating openly with your retina specialist about the treatment burden is important. The specialist may be able to adjust your regimen to reduce visits while still protecting your vision. Newer medications with longer-lasting effects may be an option for some patients.
The single most important step you can take is to attend every scheduled appointment, even if your vision seems stable. Retinal fluid can return before you notice any visual change. Only imaging can detect early recurrence. Consistent follow-up gives your retina specialist the information needed to keep your treatment on track and gives you the best chance of preserving your vision long-term.
Your retina specialist works alongside your general ophthalmologist and optometrist. Your primary eye care provider may be the one who first detects a retinal problem and refers you. After a retina specialist begins treatment, your other eye care providers can continue to manage needs like glasses prescriptions and routine eye health screenings. However, the retina specialist should remain in charge of your injection treatment and retinal monitoring.
Questions and Answers
The duration of treatment depends on the condition being treated and how your eye responds. Many patients with wet AMD, diabetic macular edema, or retinal vein occlusion require injections for years. Some patients eventually achieve stable results and can stop injections, though ongoing monitoring is still recommended. Your retina specialist will assess your retina at each visit and discuss the plan going forward.
Yes. Retina specialists sometimes switch patients from one anti-VEGF drug to another. Each medication has a slightly different formulation, and some patients respond better to one drug than another. If imaging shows that fluid persists despite regular injections, your retina specialist may recommend trying a different medication or adjusting the dose interval.
Missing multiple appointments can allow retinal fluid and abnormal blood vessel activity to return. Over time, repeated or prolonged episodes of swelling and leakage can cause permanent damage to the retinal cells responsible for central vision. Research shows that patients who receive fewer injections over time tend to have worse visual outcomes (Retina Today, 2021). If you have missed appointments, contact your retina specialist as soon as possible to resume care.
The eye is numbed with anesthetic drops before the injection, so most patients report feeling pressure rather than sharp pain. Some mild soreness or irritation may follow for a day or two. While the idea of an eye injection can be understandably uncomfortable, most patients tolerate the procedure well and find it becomes more routine over time.
Newer medications like Vabysmo (faricimab) and Eylea HD (high-dose aflibercept) may allow longer intervals between injections for some patients. The port delivery system (Susvimo) can deliver medication continuously, reducing visits to about twice per year. Your retina specialist can determine whether you are a candidate for extended-interval treatment based on how your retina responds to therapy.